4D Molecular Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

4D Molecular Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $60.24 million for the year ending 2025.

  • 4D Molecular Therapeutics, Inc. showed a decrease of -59.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from 4D Molecular Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), 4D Molecular Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 21.3%.
  • Historical annual values: Fiscal year 2025: $60.24 million | Fiscal year 2024: $149.34 million | Fiscal year 2023: $249.11 million | Fiscal year 2022: $52.35 million | Fiscal year 2021: $153.00 million | Fiscal year 2020: $276.73 million | Fiscal year 2019: $49.65 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: